Anondita Medicare (NSE:ANONDITA) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANONDITA Anondita Medicare Ltd NSE:ANONDITA
21 GF Score
Price ₹1,054.60
! 4 Warning Signs
View Full Analysis

What is Anondita Medicare Research & Development?

Anondita Medicare NSE:ANONDITA +0.68% 21 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ANONDITA with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Anondita Medicare's Research & Development for the six months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Anondita Medicare  (NSE:ANONDITA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Anondita Medicare Research & Development Related Terms

Anondita Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Anondita Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anondita Medicare Research & Development Chart

Anondita Medicare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00 0.00

Anondita Medicare Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:ANONDITA
21GF Score
Anondita Medicare Ltd NSE:ANONDITA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anondita Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Anondita Medicare (NSE:ANONDITA) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Anondita Medicare and its competitors.
Is Anondita Medicare's Research & Development too high?
Anondita Medicare's current Research & Development is ₹0 Mil. Overall, Anondita Medicare has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Anondita Medicare's Research & Development compare to PG and CL?
Anondita Medicare's Research & Development of ₹0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anondita Medicare and its competitors. Anondita Medicare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anondita Medicare stock overvalued right now?
Anondita Medicare (NSE:ANONDITA) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Anondita Medicare's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anondita Medicare (NSE:ANONDITA), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anondita Medicare Business Description

Address D-001, Sector 80, Gautam Budh Nagar, Noida, UP, IND, 201301
Anondita Medicare Ltd is a manufacturer of male condoms with a variety of flavors, with its flagship product marketed and sold under the brand COBRA. It has an installed production capacity of nearly 562 million condoms per annum.
21GF Score

Get the complete analysis for NSE:ANONDITA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,054.60
Price